References
- Thermo Scientific. Phadia 250 User Manual 2012.
- 2011 letter from Thermo Fisher Scientific; Interference Study for EliA products.
- 2014 Table from Thermo Fisher Scientific; interference in EliA tests.
- Roche Diagnostics. Cobas 8000 User manual 2017.
- Snyder JA, Rogers MW, King MS, et al. The impact of hemolysis on ortho-clinical diagnostic's ECi and Roche's elecsys immunoassay systems. Clin Chim Acta. 2004;348:181–187.
- Nikolac N. Lipemia: causes, interference mechanisms, detection and management. Biochem Med. 2014;24:57–67.
- Nikolac N, Simundic AM, Miksa M, et al. Heterogeneity of manufacturers declarations for lipemia interference - An urgent call for standardization. Clin Chim Acta. 2013;426:33–40.
- Kroll MH. Evaluating interference caused by lipemia. Clin Chem. 2004;50:1968–1969.
- Steen G, Klerk A, Laan KVD, et al. Evaluation of the interference due to haemoglobin, bilirubin and lipids on Immulite 2500 assays: a practical approach. Ann Clin Biochem. 2011;48:170–175.
- Wolf J, Haendel N, Remmler J, et al. Hemolysis and IgA-antibodies against tissue transglutaminase: when are antibody test results no longer reliable? J Clin Lab Anal. 2017. DOI: 10.1002/jcla.22360
- Arguelles-grande C, Norman GL, Bhagat G, et al. Hemolysis interferes with the detection of anti-tissue transglutaminase antibodies in celiac disease. Clin Chem. 2010;56:1034–1036.
- Brusca I. Advances in clinical chemistry. 1st ed. Palermo (Italy): Elsevier Inc; 2015. Chapter 1. Overview of biomarkers for diagnosis and monitoring of celiac disease; p. 13–14.